Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

AZD3293

- PMLiVE

Lilly pitches Cyramza at bladder cancer

Pharma firm is now armed with phase III data from its RANGE study

- PMLiVE

Recordati acquires AstraZeneca blood pressure brands

Italian pharma firm obtains Seloken and Logimax

- PMLiVE

Biogen spin-out makes first acquisition

Bioverativ attains rare disease group True North

Biogen Idec building

Biogen hands out $120m upfront for Remedy stroke drug

Cirara vying to be first new treatment since the 1990s

AstraZeneca AZ

AZ buoyed by Imfinzi lung cancer trial

Phase III study shows PD-L1 inhibitor increased progression-free survival

- PMLiVE

Eli Lilly appoints senior VP for corporate affairs and communications

Leigh Ann Pusey joins from the American Insurance Association

Sanofi targets patient literacy in clinical trials drive

Unveils new online resources for those in the US

AstraZeneca AZ

AZ gets first OK for PD-L1 inhibitor durvalumab

US regulators also approve Roche’s Ventana

Eli Lilly HQ

Surging Trulicity takes sting out of Lilly’s arthritis setback

First quarter sales of the diabetes treatment were up by 160%, exceeding analysts predictions

EU flag

CHMP backs two rare disease therapies at April meeting

Biogen's Spinraza and BioMarin's Brineura near EU approval

Eli Lilly HQ

FDA turns down Lilly and Incyte JAK inhibitor after delay

Analysts suggest safety issues in high doses

Deal Watch March 2017

Sanofi, MedImmune, AstraZeneca, Astellas, Novartis and more feature in this month's pharma deals round-up

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links